Esperion Therapeutics (ESPR) Profit After Tax (2012 - 2026)

Esperion Therapeutics' Profit After Tax history runs 15 years deep, the most recent figure standing at -$25.2 million for Q1 2026.

• Quarterly Profit After Tax rose 37.72% year-over-year to -$25.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$7.4 million (up 95.16% YoY) and the FY2025 annual result came in at -$22.7 million, up 56.17% from the prior year.
• Profit After Tax was -$25.2 million for Q1 2026 at Esperion Therapeutics, down from $61.8 million in the prior quarter.
• Across five years, Profit After Tax topped out at $61.8 million in Q4 2025 and bottomed at -$66.3 million in Q2 2022.
• A 5-year average of -$31.9 million and a median of -$41.2 million in 2023 frame the typical range for Profit After Tax.
• Peak annual rise in Profit After Tax reached 390.04% in 2025, while the deepest fall reached 166.3% in 2025.
• Esperion Therapeutics' Profit After Tax stood at -$55.4 million in 2022, then slipped by 1.66% to -$56.3 million in 2023, then jumped by 62.16% to -$21.3 million in 2024, then jumped by 390.04% to $61.8 million in 2025, then sank by 140.75% to -$25.2 million in 2026.
• Business Quant data shows ESPR's Profit After Tax at -$25.2 million in Q1 2026, $61.8 million in Q4 2025, and -$31.3 million in Q3 2025.